A Study of Imaging to Detect HER2 Positive Cancer Cells in Women with Breast Cancer, to Guide the Use of HER2 Targeted Therapies

Full Title

Can HER2 targeted PET/CT imaging identify unsuspected HER2 positive breast cancer metastases, which are amenable to HER2 targeted therapy?

Purpose

Drugs like trastuzumab and lapatinib target a protein on some breast cancer cells called HER2. Patients with HER2 positive cancer cells benefit from treatment with these drugs. Patients whose biopsies do not show HER2 positive cancer cells do not receive these drugs. But a biopsy only looks at one or a few sites of cancer cells.

The purpose of this study is to determine if positron emission tomography (PET)/computed tomography (CT) imaging, using a trastuzumab radiotracer, can identify patients with HER2 positive cancer cells that were not found on biopsy. Patients with newly discovered HER2 positive cancer may benefit from drugs that attack HER2.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have HER2 negative metastatic breast cancer
  • Patients may not have previously received treatments that target HER2.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for women over age 18.

For more information about this study and to inquire about eligibility, please contact Dr. Gary Ulaner at 212-639-3776.

Protocol

14-156

Phase

Pilot

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators

Carrasquillo, Jorge, MD

Diseases